- AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Ph 1b in prostate cancer
- Akeso Inc. presents data from the registrational Ph 3 AK112-306/HARMONi-6 study of ivonescimab in 1L sq-NSCLC
- Antengene Presents ATG-022 Clinical data Demonstrating Efficacy Across All CLDN18.2 Expression Levels and Exceptional Tolerability
- Artios Announces Ph 1/2a Data for ART6043
- Arvinas Presents Data from the Vepdegestrant Clinical Development Program
- Avacta Therapeutics presents compelling Ph 1a data for faridoxorubicin and the pre|CISION® platform
- BioAtla Presents Interim Data from Ph 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma
- Boehringer’s zongertinib demonstrated a 77% ORR in 1L HER2 (ERBB2)-mutant NSCLC
- BPGbio Presents Ph 2 Glioblastoma Data on BPM31510
- BriaCell Presents Positive Clinical Biomarker Data of Ph 3 Study of Bria-IMT™ in metastatic breast cancer (MBC)
- CARsgen Presents Preliminary Results on Satri-cel for Adjuvant Therapy of Pancreatic Cancer
- Celcuity Presents Updated Data from Ph 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with mCRPC
- Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers
- Corvus Pharmaceuticals Announces Presentation of Interim Data from the Ph 1b/2 Trial of Ciforadenant for Patients with Metastatic RCC
- CStone Discloses Ph 1 Data for CS2009
- DATROWAY + Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Ph 2 Trial
- Datroway demonstrated an unprecedented median OS improvement of five months vs. chemo as 1L treatment for patients with mTNBC for whom immunotherapy was not an option in TROPION-Breast02
- Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
- DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Ph 1/2 Trial
- Eikon Therapeutics to Present New Ph 2 Data on EIK1001 in 1L NSCLC
- Enhertu followed by THP before surgery resulted in a pCR in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Ph 3 trial
- Enhertu reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Ph 3 trial
- Evaxion reports 75% ORR in Ph 2 trial with AI-designed personalized cancer vaccine EVX-01
- Exelixis Announces Detailed Results from Ph 3 STELLAR-303 Pivotal Trial of Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in mCRC
- General Oncology Announces Promising Preliminary Ph 1 Results from SHARON Trial
- Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
- Hansoh Pharma Announces Proffered Paper Presentation of Ph 2 Study on HS-20093 in R/R Sarcomas
- Hansoh Pharma Presents the Ph 2 study findings of HS-20089 (B7-H4-targeted ADC), in patients with platinum-resistant ovarian cancer (PROC)
- HUTCHMED Highlights FRUSICA-2 Registration Trial Data
- IDEAYA Biosciences Announces Positive Ph 2 Data for Darovasertib in the Neoadjuvant Setting of Primary Uveal Melanoma
- Imfinzi-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Ph 3 trial
- Imfinzi regimen reduced the risk of disease recurrence or death by 32% in high-risk NMIBC in the POTOMAC Ph 3 trial
- Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma
- IMUNON to Present Ph 3 Ovarian Cancer Study of IMNN-001
- ImmunOs Therapeutics Reports Promising Clinical Activity of IOS-1002 in Advanced Solid Tumors
- Incyte Announces Ph 1 Results for TGFβR2×PD-1 Bispecific Antibody in Advanced CRC and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
- IO Biotech Presents Ph 3 Results for Cylembio + KEYTRUDA in 1L Advanced Melanoma
- iOnctura presents cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer
- ITM Announces Ph 3 COMPETE Data Demonstrating a Statistically Significant Higher ORR with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with GEP-NETs
- Ivonescimab + Chemo Reduced the Risk of Disease Progression or Death by 40% vs Tislelizumab + Chemo in 1L Squamous NSCLC in the HARMONi-6 Study
- Kelun-Biotech Presents Positive Ph 3 Data for Trastuzumab Botidotin Compared to T-DM1
- KEYTRUDA® Demonstrates Long-Term Survival Benefit in Certain Patients With Earlier or Advanced Stages of NSCLC
- KEYTRUDA® + Chemo With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
- KEYTRUDA® + Padcev® (enfortumab vedotin-ejfv) Reduced Risk of EFS Events by 60% and Risk of Death by 50% for Certain Patients with MIBC When Given Before and After Surgery
- KEYTRUDA® + LENVIMA® (lenvatinib) Demonstrates Durable 5-Year Survival Benefit Versus Chemo for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
- Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs
- Leap Therapeutics Presents Final Data from DeFianCe Study
- Lilly’s Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment
- Mabwell Announces Latest Clinical Results of Novel B7-H3-Targeting ADC 7MW3711
- Marengo Presents Initial Ph 2 Results Demonstrating Broad Single-Agent Activity of Invikafusp Alfa Across Multiple PD-1-Refractory or -Resistant Solid Tumors
- Merck Announces Ph 3 KEYNOTE-B96 Trial Met Secondary Endpoint of OS in All Comers Population of Patients With Platinum-Resistant Recurrent Ovarian Cancer
- Moderna announced clinical, safety and translational data from Ph 1/2 study of mRNA-4359 + pembrolizumab in CPI-R/R melanoma patients
- Multitude Therapeutics Announces Interim Ph 1/2 AMT-253 trial in Melanoma and Other Advanced Solid Tumors
- New AlphaMedix data showed sustained and clinically meaningful responses across both RLTnaïve and RLT-exposed patients with unresectable or metastatic GEP-NETs
- New safety and PK data from Ph 3 C-POST trial provide insights on an every 6-week dosing regimen of adjuvant Libtayo® (cemiplimab) in high-risk CSCC
- Nouscom Presents Positive Ph 2 Results of NOUS-209 Combined with Pembrolizumab in MSI-H mCRC Patients Refractory to Anti-PD-1 Therapy
- Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population
- Nurix Therapeutics Reports New Clinical Data from NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types
- Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond NSCLC
- Olema Oncology Announces New Data from the Ph 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer
- Patient-Reported Outcomes from VERITAC-2 Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy
- Perspective Therapeutics Presents Updated Interim Data from Ongoing Ph 1/2a Trial of [212Pb]VMT-α-NET
- Positive Results from Ph 3 OptiTROP-Lung04 Trial of Sacituzumab Tirumotecan presented
- Primary Endpoint Met in EFTISARC-NEO Ph 2 of Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented
- PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
- Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Ph 2 Part of REJOICE-Ovarian01 Ph 2/3 Trial
- Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
- Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab
- Roche’s Tecentriq showed significant OS and DFS benefits in bladder cancer with ctDNA-guided treatment
- Roche’s Ph 2 evERA data showed giredestrant significantly improved PFS in people with ER-positive advanced breast cancer
- SC amivantamab delivers promising 45% ORR with median duration of 7.2 months in recurrent or metastatic head and neck cancer
- SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma
- Sensei Biotherapeutics Reports New Clinical Results Highlighting Durable PFS Data for Solnerstotug in PD-(L)1 Resistant Tumors
- Significant OS Benefit with Cadonilimab in 1L Advanced Gastric Cancer: Final Analysis of COMPASSION-15 Presented
- SystImmune, Inc. and BMS Announce First Global Ph 1 Results of Iza-bren in Patients with Advanced Solid Tumors
- Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR Mutations and Active Brain Metastases
- Theolytics to Present Ongoing Ph 1/2a OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer
- TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy
- Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
- Trodelvy® Reduces Risk of Disease Progression or Death by 38% Versus Chemo as 1L Therapy in Patients With mTNBC in ASCENT-03 Study
- Tubulis Presents First Clinical Data from Ph 1/2a Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC)